Presbyopia lens launch

Article

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

The main feature of this multifocal lens is its aspheric multi-curve design comprising a segment shaped near-vision section characterized by seamless transitions between the near and far vision zones.

Various benefits for the patient are said to result from this innovative design. In particular, reflections and image jumps as usually in twilight light conditions or in central headlight glare conditions will no longer occur. Furthermore the MIOL is pupil independent, offers true +3 D addition and ensures a minimal loss of light.

A multi-center study conducted under the leadership of Professor G. U. Auffarth of Heidelberg University Eye Clinic analyzed the results obtained by the implantation of the lens in 114 eyes of 69 patients (mean age: 68 ± 12 years). Oculentis says this confirmed the functional outcomes achieved with the MIOL as well as a very high degree of patient satisfaction. No complications were seen in both, unilateral and bilateral implantation. Mean IOL power came to 21.00 ± 2.01 D Three months after surgery, a best corrected distance visual acuity of 0.01 ± 0.14 logMAR was measured. Uncorrected near visual acuity came to 0.08 ± 0.17 logMAR.

Using the computer-controlled SML technology, each LENTIS Mplus IOL will be customized to the special needs of the individual patient and is made from the well-proved HydroSmart material.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.